STOCK TITAN

Clever Leaves to Hold Third Quarter 2021 Conference Call on November 10, 2021 at 5:00 p.m. ET

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BOCA RATON, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, will hold a conference call on Wednesday, November 10, 2021 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2021. The Company will provide its financial results in a press release prior to the conference call.

Clever Leaves management will host the conference call, followed by a question and answer session.

Conference Call Date: November 10, 2021
Time: 5:00 p.m. Eastern time
Toll-free dial-in number: 1-844-826-3033
International dial-in number: 1-412-317-5185
Conference ID: 10161398

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at (949) 574-3860.

The conference call will be broadcast live and available for replay here.

A telephonic replay of the conference call will also be available after 8:00 p.m. Eastern time on the same day through November 17, 2021.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 10161398

About Clever Leaves Holdings Inc.

Clever Leaves is a multinational cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade cannabinoid processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry’s leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was also granted certification of compliance with GACP and IMC-GAP.

Clever Leaves Investor Inquiries:
Cody Slach or Jackie Keshner
Gateway Investor Relations
+1-949-574-3860
CLVR@gatewayir.com

Clever Leaves Press Contacts:
McKenna Miller
KCSA Strategic Communications
+1-347-487-6197
mmiller@kcsa.com

Diana Sigüenza
Strategic Communications Director
+57-310-236-8830
diana.siguenza@cleverleaves.com

Clever Leaves Commercial Inquiries:
Andrew Miller
Vice President Sales - EMEA, North America, and Asia-Pacific
+1-416-817-1336
andrew.miller@cleverleaves.com

Project Change Lives Inquiries:
PCLInquiries@cleverleaves.com


Clever Leaves Holdings Inc.

OTC:CLVR

CLVR Rankings

CLVR Latest News

CLVR Stock Data

5.26M
1.63M
12.39%
7.39%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TOCANCIPA - CUNDINAMARCA

About CLVR

clever leaves, a colombian company fully-licensed, will become the world’s largest grower with over 10mm+ ft2 of cultivation capacity by 2023, the largest extractor with pharmaceutical grade and gmp certified processing facilities, and the lowest cost operator in cannabis exports. one of the first colombian license holders in the medical cannabis industry. a company positioned to become a leader in the global market with a differentiated business model and strong positioning with regulators, physicians, and other relevant players. developing key capabilities to win in the new space of the medical cannabis industry with a highly experienced and respected team.